Summary: The U.S. Food and Drug Administration (FDA) requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing Zelnorm® (tegaserod) because patients who take the drug may have an increased risk of developing heart problems. For more information on integrative therapies visit www.naturalstandard.com.
